Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060610" target="_blank" >RIV/00216224:14110/12:00060610 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.074" target="_blank" >http://dx.doi.org/10.1016/j.lungcan.2012.05.074</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.074" target="_blank" >10.1016/j.lungcan.2012.05.074</a>

Result language

angličtina

Original language name

Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)

Original language description

The Czech Republic has had an opportunity to use pemetrexed for 1st line treatment of advanced NSCLC from the year 2008. The purpose of this trial was to evaluate the activity and feasibility of pemetrexed in 1st line treatment NSCLC patients.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů